The first targeted therapy in pediatric solid tumors

Prof. Gilles Vassal, director of clinical research at Gustave Roussy, explains the results of studies presented at ASCO 2019 on larotrectinib, a TRK inhibitor: this is the first targeted therapy for pediatric solid tumors, regardless of tumor type.
+